GI Innovation KRX:358570KOSDAQ
지아이이노베이션 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, GI Innovation reported an operating loss of ₩14.4bn. GI Innovation (지아이이노베이션) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Clinical trial filing 4 quarters of losses Screener
GI Innovation quarterly results separate, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q2 2026 | −₩14.4bn | −₩14.3bn |
| Q1 2026 | −₩12.4bn | −₩12.3bn |
| Q4 2025 derived | −₩7.2bn | −₩3.1bn |
| Q3 2025 | −₩10.7bn | −₩9.5bn |
| Q2 2025 | −₩10.9bn | −₩9.8bn |
| Q1 2025 | −₩11.8bn | −₩12.8bn |
| Q4 2024 derived | −₩12.2bn | −₩20.0bn |
| Q3 2024 | −₩13.8bn | −₩14.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
GI Innovation top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest GI Innovation news Korean headlines
No articles yet.